Over the past ten quarters, spanning 2023 to June 2025, Twist Bioscience Corp. (TWST) has delivered consistent revenue growth while tightening its belt on losses. With momentum building and a breakeven target on the horizon for fiscal 2026, is it time to take a closer look at the stock?
Twist Bioscience is a synthetic biology company with a disruptive DNA synthesis platform that uses proprietary technology to "write" DNA on a silicon chip, pioneering a new method of manufacturing synthetic DNA. This unique technology is used to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing or NGS, sample preparation, and antibody libraries for drug discovery and development. The synthetic DNA and synthetic DNA-based products are sold to customers across multiple industries, including healthcare, chemicals/materials, food/agriculture, and academic research, serving a global customer base of about 3,562 customers.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.